Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 69

1.

Nanomedicines in the treatment of brain tumors.

Fisusi FA, Schätzlein AG, Uchegbu IF.

Nanomedicine (Lond). 2018 Mar;13(6):579-583. doi: 10.2217/nnm-2017-0378. Epub 2018 Jan 29. No abstract available.

2.

Nanoparticulate peptide delivery exclusively to the brain produces tolerance free analgesia.

Godfrey L, Iannitelli A, Garrett NL, Moger J, Imbert I, King T, Porreca F, Soundararajan R, Lalatsa A, Schätzlein AG, Uchegbu IF.

J Control Release. 2018 Jan 28;270:135-144. doi: 10.1016/j.jconrel.2017.11.041. Epub 2017 Nov 27.

3.

Preface.

Uchegbu IF.

Pharm Nanotechnol. 2017;5(1):2. doi: 10.2174/221173850501170316193147. No abstract available.

PMID:
28948906
4.

T-shaped Peptide Amphiphiles Self Assemble into Nanofiber Networks.

Fisusi FA, Notman R, Granger LA, Malkinson JP, Schatzlein AG, Uchegbu IF.

Pharm Nanotechnol. 2017;5(3):215-219. doi: 10.2174/2211738505666170828095937.

PMID:
28847269
5.

Preface.

Uchegbu IF.

Pharm Nanotechnol. 2017;5(2):82. doi: 10.2174/221173850502170706223013. No abstract available.

PMID:
28758588
6.

Limiting the level of tertiary amines on polyamines leads to biocompatible nucleic acid vectors.

Simão Carlos MI, Zheng K, Garrett N, Arifin N, Workman DG, Kubajewska I, Halwani AA, Moger J, Zhang Q, Schätzlein AG, Uchegbu IF.

Int J Pharm. 2017 Jun 30;526(1-2):106-124. doi: 10.1016/j.ijpharm.2017.04.059. Epub 2017 Apr 25.

PMID:
28450169
7.

Nose to brain delivery in rats: Effect of surface charge of rhodamine B labeled nanocarriers on brain subregion localization.

Bonaccorso A, Musumeci T, Serapide MF, Pellitteri R, Uchegbu IF, Puglisi G.

Colloids Surf B Biointerfaces. 2017 Jun 1;154:297-306. doi: 10.1016/j.colsurfb.2017.03.035. Epub 2017 Mar 18.

PMID:
28363190
8.

Lomustine Nanoparticles Enable Both Bone Marrow Sparing and High Brain Drug Levels - A Strategy for Brain Cancer Treatments.

Fisusi FA, Siew A, Chooi KW, Okubanjo O, Garrett N, Lalatsa K, Serrano D, Summers I, Moger J, Stapleton P, Satchi-Fainaro R, Schätzlein AG, Uchegbu IF.

Pharm Res. 2016 May;33(5):1289-303. doi: 10.1007/s11095-016-1872-x. Epub 2016 Feb 22.

9.

Oral particle uptake and organ targeting drives the activity of amphotericin B nanoparticles.

Serrano DR, Lalatsa A, Dea-Ayuela MA, Bilbao-Ramos PE, Garrett NL, Moger J, Guarro J, Capilla J, Ballesteros MP, Schätzlein AG, Bolás F, Torrado JJ, Uchegbu IF.

Mol Pharm. 2015 Feb 2;12(2):420-31. doi: 10.1021/mp500527x. Epub 2015 Jan 15.

PMID:
25558881
10.

Chitosan amphiphile coating of peptide nanofibres reduces liver uptake and delivers the peptide to the brain on intravenous administration.

Lalatsa A, Schätzlein AG, Garrett NL, Moger J, Briggs M, Godfrey L, Iannitelli A, Freeman J, Uchegbu IF.

J Control Release. 2015 Jan 10;197:87-96. doi: 10.1016/j.jconrel.2014.10.028. Epub 2014 Nov 5.

11.

Physical characterisation and long-term stability studies on quaternary ammonium palmitoyl glycol chitosan (GCPQ)--a new drug delivery polymer.

Chooi KW, Simão Carlos MI, Soundararajan R, Gaisford S, Arifin N, Schätzlein AG, Uchegbu IF.

J Pharm Sci. 2014 Aug;103(8):2296-306. doi: 10.1002/jps.24026. Epub 2014 Jun 10.

PMID:
24916193
12.

Optimisation of synthetic vector systems for cancer gene therapy - the role of the excess of cationic dendrimer under physiological conditions.

Santander-Ortega MJ, de la Fuente M, Lozano MV, Tsui ML, Bolton K, Uchegbu IF, Schätzlein AG.

Curr Top Med Chem. 2014;14(9):1172-81.

PMID:
24678705
13.

Strategies to deliver peptide drugs to the brain.

Lalatsa A, Schatzlein AG, Uchegbu IF.

Mol Pharm. 2014 Apr 7;11(4):1081-93. doi: 10.1021/mp400680d. Epub 2014 Mar 21. Review.

PMID:
24601686
14.

Claw amphiphiles with a dendrimer core: nanoparticle stability and drug encapsulation are directly proportional to the number of digits.

Chooi KW, Hou XL, Qu X, Soundararajan R, Uchegbu IF.

Langmuir. 2013 Apr 2;29(13):4214-24. doi: 10.1021/la304909r. Epub 2013 Mar 22.

PMID:
23473107
15.

Dextran-pegylated microparticles for enhanced cellular uptake of hydrophobic drugs.

Cassano R, Ferrarelli T, Schätzlein AG, Uchegbu IF, Trombino S.

Eur J Pharm Biopharm. 2013 Aug;84(3):540-8. doi: 10.1016/j.ejpb.2013.01.017. Epub 2013 Feb 16.

PMID:
23419813
16.

The oral delivery of amphotericin B.

Torrado JJ, Serrano DR, Uchegbu IF.

Ther Deliv. 2013 Jan;4(1):9-12. No abstract available.

PMID:
23401912
17.

Nanofiber-based delivery of therapeutic peptides to the brain.

Mazza M, Notman R, Anwar J, Rodger A, Hicks M, Parkinson G, McCarthy D, Daviter T, Moger J, Garrett N, Mead T, Briggs M, Schätzlein AG, Uchegbu IF.

ACS Nano. 2013 Feb 26;7(2):1016-26. doi: 10.1021/nn305193d. Epub 2013 Jan 10.

PMID:
23289352
18.

Nanomedicines and nanodiagnostics come of age.

Uchegbu IF, Siew A.

J Pharm Sci. 2013 Feb;102(2):305-10. doi: 10.1002/jps.23377. Epub 2012 Nov 22. Review.

PMID:
23175462
19.

Amphiphilic poly(L-amino acids) - new materials for drug delivery.

Lalatsa A, Schätzlein AG, Mazza M, Le TB, Uchegbu IF.

J Control Release. 2012 Jul 20;161(2):523-36. doi: 10.1016/j.jconrel.2012.04.046. Epub 2012 May 18. Review.

PMID:
22613882
20.

A prodrug nanoparticle approach for the oral delivery of a hydrophilic peptide, leucine(5)-enkephalin, to the brain.

Lalatsa A, Lee V, Malkinson JP, Zloh M, Schätzlein AG, Uchegbu IF.

Mol Pharm. 2012 Jun 4;9(6):1665-80. doi: 10.1021/mp300009u. Epub 2012 May 18.

PMID:
22574705
21.

Delivery of peptides to the blood and brain after oral uptake of quaternary ammonium palmitoyl glycol chitosan nanoparticles.

Lalatsa A, Garrett NL, Ferrarelli T, Moger J, Schätzlein AG, Uchegbu IF.

Mol Pharm. 2012 Jun 4;9(6):1764-74. doi: 10.1021/mp300068j. Epub 2012 May 21.

PMID:
22571402
22.

Nanotechnology in advanced drug delivery.

Jain S, Uchegbu IF, Betageri G, Pastorin G.

J Drug Deliv. 2011;2011:343082. doi: 10.1155/2011/343082. Epub 2011 Oct 25. No abstract available.

23.

Polyamine aza-cyclic compounds demonstrate anti-proliferative activity in vitro but fail to control tumour growth in vivo.

Wong PE, Tetley L, Dufès C, Chooi KW, Bolton K, Schätzlein AG, Uchegbu IF.

J Pharm Sci. 2010 Nov;99(11):4642-57. doi: 10.1002/jps.22165.

PMID:
20845462
24.

In silico modelling of drug-polymer interactions for pharmaceutical formulations.

Ahmad S, Johnston BF, Mackay SP, Schatzlein AG, Gellert P, Sengupta D, Uchegbu IF.

J R Soc Interface. 2010 Aug 6;7 Suppl 4:S423-33. doi: 10.1098/rsif.2010.0190.focus. Epub 2010 Jun 2.

25.

The molecular shape of poly(propylenimine) dendrimer amphiphiles has a profound effect on their self assembly.

Chooi KW, Gray AI, Tetley L, Fan Y, Uchegbu IF.

Langmuir. 2010 Feb 16;26(4):2301-16. doi: 10.1021/la9027282.

PMID:
19860445
26.

The complexation between novel comb shaped amphiphilic polyallylamine and insulin: towards oral insulin delivery.

Thompson CJ, Tetley L, Uchegbu IF, Cheng WP.

Int J Pharm. 2009 Jul 6;376(1-2):46-55. doi: 10.1016/j.ijpharm.2009.04.014. Epub 2009 Apr 16.

PMID:
19375489
27.

Cancer-specific transgene expression mediated by systemic injection of nanoparticles.

Chisholm EJ, Vassaux G, Martin-Duque P, Chevre R, Lambert O, Pitard B, Merron A, Weeks M, Burnet J, Peerlinck I, Dai MS, Alusi G, Mather SJ, Bolton K, Uchegbu IF, Schatzlein AG, Baril P.

Cancer Res. 2009 Mar 15;69(6):2655-62. doi: 10.1158/0008-5472.CAN-08-2657. Epub 2009 Mar 3.

28.

Polymeric amphiphile branching leads to rare nanodisc shaped planar self-assemblies.

Qu X, Omar L, Le TB, Tetley L, Bolton K, Chooi KW, Wang W, Uchegbu IF.

Langmuir. 2008 Sep 16;24(18):9997-10004. doi: 10.1021/la8007848. Epub 2008 Aug 9.

PMID:
18690736
29.

Cancer and the blood-brain barrier: 'Trojan horses' for courses?

Mazza M, Uchegbu IF, Schätzlein AG.

Br J Pharmacol. 2008 Sep;155(2):149-51. doi: 10.1038/bjp.2008.274. Epub 2008 Jun 30.

30.

High-resolution 3D isotropic MR imaging of mouse flank tumours obtained in vivo with solenoid RF micro-coil.

Holmes WM, Maclellan S, Condon B, Dufès C, Evans TR, Uchegbu IF, Schätzlein AG.

Phys Med Biol. 2008 Jan 21;53(2):505-13. doi: 10.1088/0031-9155/53/2/015. Epub 2007 Dec 28.

PMID:
18185002
31.

Carbohydrate-based micelle clusters which enhance hydrophobic drug bioavailability by up to 1 order of magnitude.

Qu X, Khutoryanskiy VV, Stewart A, Rahman S, Papahadjopoulos-Sternberg B, Dufes C, McCarthy D, Wilson CG, Lyons R, Carter KC, Schätzlein A, Uchegbu IF.

Biomacromolecules. 2006 Dec;7(12):3452-9.

PMID:
17154474
32.

Pharmaceutical nanotechnology: polymeric vesicles for drug and gene delivery.

Uchegbu IF.

Expert Opin Drug Deliv. 2006 Sep;3(5):629-40. Review.

PMID:
16948558
33.

Polyelectrolyte nanoparticles with high drug loading enhance the oral uptake of hydrophobic compounds.

Cheng WP, Gray AI, Tetley L, Hang Tle B, Schätzlein AG, Uchegbu IF.

Biomacromolecules. 2006 May;7(5):1509-20.

PMID:
16677033
34.

Dendrimers in gene delivery.

Dufès C, Uchegbu IF, Schätzlein AG.

Adv Drug Deliv Rev. 2005 Dec 14;57(15):2177-202. Epub 2005 Nov 28. Review.

PMID:
16310284
35.

Tumour gene expression from C12 spermine amphiphile gene delivery systems.

Kan PL, Gray AI, Tetley L, Converse CA, Schätzlein AG, Uchegbu IF.

J Drug Target. 2005 Jul;13(6):345-57.

PMID:
16278154
36.

Synthetic anticancer gene medicine exploits intrinsic antitumor activity of cationic vector to cure established tumors.

Dufès C, Keith WN, Bilsland A, Proutski I, Uchegbu IF, Schätzlein AG.

Cancer Res. 2005 Sep 15;65(18):8079-84.

37.
38.

Gene transfer with three amphiphilic glycol chitosans--the degree of polymerisation is the main controller of transfection efficiency.

Uchegbu IF, Sadiq L, Pardakhty A, El-Hammadi M, Gray AI, Tetley L, Wang W, Zinselmeyer BH, Schätzlein AG.

J Drug Target. 2004;12(8):527-39.

PMID:
15621678
39.

Preferential liver gene expression with polypropylenimine dendrimers.

Schatzlein AG, Zinselmeyer BH, Elouzi A, Dufes C, Chim YT, Roberts CJ, Davies MC, Munro A, Gray AI, Uchegbu IF.

J Control Release. 2005 Jan 3;101(1-3):247-58.

PMID:
15588909
40.

Glucose-targeted niosomes deliver vasoactive intestinal peptide (VIP) to the brain.

Dufes C, Gaillard F, Uchegbu IF, Schätzlein AG, Olivier JC, Muller JM.

Int J Pharm. 2004 Nov 5;285(1-2):77-85.

PMID:
15488681
41.

Drug transport and drug delivery--the Midnight Sun meeting.

Uchegbu IF.

IDrugs. 2004 Aug;7(8):743-5.

PMID:
15334307
42.

PEI-based vesicle-polymer hybrid gene delivery system with improved biocompatibility.

Brownlie A, Uchegbu IF, Schätzlein AG.

Int J Pharm. 2004 Apr 15;274(1-2):41-52.

PMID:
15072781
43.

Evaluation of generation 2 and 3 poly(propylenimine) dendrimers for the potential cellular delivery of antisense oligonucleotides targeting the epidermal growth factor receptor.

Hollins AJ, Benboubetra M, Omidi Y, Zinselmeyer BH, Schatzlein AG, Uchegbu IF, Akhtar S.

Pharm Res. 2004 Mar;21(3):458-66.

PMID:
15070097
44.

Glucose-receptor MR imaging of tumors: study in mice with PEGylated paramagnetic niosomes.

Luciani A, Olivier JC, Clement O, Siauve N, Brillet PY, Bessoud B, Gazeau F, Uchegbu IF, Kahn E, Frija G, Cuenod CA.

Radiology. 2004 Apr;231(1):135-42. Epub 2004 Feb 27.

PMID:
15068944
45.

Anticancer drug delivery with transferrin targeted polymeric chitosan vesicles.

Dufes C, Muller JM, Couet W, Olivier JC, Uchegbu IF, Schätzlein AG.

Pharm Res. 2004 Jan;21(1):101-7.

PMID:
14984263
46.

In vitro and in vivo gene transfer with poly(amino acid) vesicles.

Brown MD, Gray AI, Tetley L, Santovena A, Rene J, Schätzlein AG, Uchegbu IF.

J Control Release. 2003 Dec 5;93(2):193-211.

PMID:
14636725
47.

Quantification of beta-galactosidase activity after non-viral transfection in vivo.

Zinselmeyer BH, Beggbie N, Uchegbu IF, Schätzlein AG.

J Control Release. 2003 Aug 28;91(1-2):201-8.

PMID:
12932652
48.

Sustained buccal delivery of the hydrophobic drug denbufylline using physically cross-linked palmitoyl glycol chitosan hydrogels.

Martin L, Wilson CG, Koosha F, Uchegbu IF.

Eur J Pharm Biopharm. 2003 Jan;55(1):35-45.

PMID:
12551702
49.

The lower-generation polypropylenimine dendrimers are effective gene-transfer agents.

Zinselmeyer BH, Mackay SP, Schatzlein AG, Uchegbu IF.

Pharm Res. 2002 Jul;19(7):960-7.

PMID:
12180548
50.

The release of model macromolecules may be controlled by the hydrophobicity of palmitoyl glycol chitosan hydrogels.

Martin L, Wilson CG, Koosha F, Tetley L, Gray AI, Senel S, Uchegbu IF.

J Control Release. 2002 Apr 23;80(1-3):87-100.

PMID:
11943390

Supplemental Content

Loading ...
Support Center